Egrifta (Tesamorelin) Online: Cost, Candidacy, and What the Evidence Shows

HealthRX.com

Tesamorelin is prescription-only and approved for one use

Print or save as PDF

Key numbers

  • 15.2%Visceral fat change on tesamorelin in the 412-patient pivotal trial at 26 weeksSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1.4 mgDaily dose of Egrifta SV, one of two products that are not substitutableSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 95 cmMinimum waist circumference in men to enter the pivotal trialsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 5%Share of tesamorelin patients with HbA1c of 6.5% or higher by week 26, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

Tesamorelin and visceral fat in HIV lipodystrophy: trials and meta-analyses

In a randomized placebo-controlled trial of 404 HIV-infected patients, Falutz 2010 reported visceral fat down 10.9% with tesamorelin versus 0.6% with placebo over 6 months. Falutz 2005, a randomized double-blind trial of 61 patients, found the visceral fat change not significant versus placebo.

Tesamorelin and visceral fat in HIV lipodystrophy: trials and meta-analyses: the figures
MeasureValueNote
Human: Falutz 2010, randomized placebo-controlled, 404 HIV-infected patientsVAT -10.9% vs -0.6% placeboInitial VAT improvements were rapidly lost in patients switching from tesamorelin to placebo. PMID 20101189
Human: Badran 2026, meta-analysis of 5 RCTs, adults with HIVvisceral fat fell, MD -27.71 cm²Tesamorelin was associated with significantly reduced visceral adipose tissue versus placebo. PMID 41545261
Human: Falutz 2005, randomized double-blind trial, 61 HIV-infected patientsVAT change not significant vs placeboTrunk fat fell in the highest-dose group; visceral fat change was not significant versus placebo. PMID 16052083
Human: Ditta 2026, meta-analysis of 4 trials, 909 patientsvisceral fat reduced (MD -21.47)Tesamorelin reduced visceral fat; the authors say long-term durability is uncertain. PMID 42538058
Human: Falutz 2010, pooled analysis of 2 trials, 806 ART-treated HIV patientsVAT treatment effect -15.4% at wk 26Visceral fat reduction was maintained for up to 52 weeks in patients who kept taking tesamorelin. PMID 20554713

Source: PubMed, National Library of Medicine, data as of Nov 13, 2026

How this was calculated

PubMed title and abstract search on 2026-11-13 for tesamorelin, Egrifta, Egrifta SV with visceral fat, visceral adipose tissue, lipodystrophy, HIV-associated lipodystrophy: 50 records, 12 abstracts read, 5 listed, each row summarising its own abstract.

Scope: Tesamorelin effects on visceral fat in HIV lipodystrophy: 5 human, 0 animal and 0 laboratory studies of 50 PubMed records.

Download the data (CSV)

See the public record for Tesamorelin

  • Drug class / growth hormone-releasing factor (GHRH) analog; a peptide, not growth hormone [2]
  • FDA-approved use / reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]
  • Approved products / Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, once-daily subcutaneous injections that are not substitutable [2][3]
  • First approval / November 10, 2010, application BLA 022505 [1]
  • Boxed warning / none in the current Egrifta SV or Egrifta WR label [2][3]
  • Key trial result / visceral fat -15.2% on tesamorelin versus +5.0% on placebo at 26 weeks, 412 patients [6]
  • Compounding / FDA has made no category-based statement about compounding tesamorelin [13][14][15]
  • Sport / named in WADA category S2.2.4 and prohibited at all times [7]

What tesamorelin is and what it is approved for

Tesamorelin is a synthetic analog of human growth hormone-releasing factor: the 44-amino-acid human sequence with a hexenoyl group on the N-terminal tyrosine, molecular weight about 5,135.9 Da [2]. It is a peptide, not growth hormone. In vitro it binds and stimulates human GRF receptors on pituitary somatotroph cells about as potently as the body's own GRF, so the pituitary makes and releases more of its own growth hormone, which in turn raises IGF-1 and IGFBP-3 [2]. No clinically significant changes in TSH, LH, ACTH or prolactin were seen in the trials [2].

Egrifta (tesamorelin acetate) was first approved on November 10, 2010 under application BLA 022505 [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026, both once-daily subcutaneous injections [2][3].

The approved indication is narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label adds four limits. Long-term cardiovascular safety has not been established. The risk and benefit of continuing should be considered in patients who have not had a reduction in visceral adipose tissue. It is not indicated for weight loss management, because its effect on weight is neutral. And there are no data showing it improves adherence to antiretroviral therapy [2]. Neither current label carries a boxed warning [2][3].

Who is a candidate

The label population is HIV-infected adults with lipodystrophy and excess abdominal fat [2]. The two pivotal trials enrolled adults aged 18 to 65 with a waist circumference of at least 95 cm (37.4 inches) and a waist-to-hip ratio of at least 0.94 in men, or at least 94 cm (37.0 inches) and 0.88 in women, with fasting blood glucose below 150 mg/dL, on a stable antiretroviral regimen for at least 8 weeks [2]. The trials excluded people with a BMI of 20 kg/m2 or less, type 1 or type 2 diabetes, prior treatment with insulin or oral glucose-lowering drugs, a history of malignancy, or hypopituitarism [2]. Those were entry rules for a trial, not a general checklist, but they show the population the drug was actually tested in.

The contraindications are explicit in both labels: disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or pituitary surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3]. The label says any preexisting malignancy should be inactive with its treatment complete before therapy starts [2]. Safety and effectiveness in children have not been established, and the labels state there is no information on use in people over 65 [2]. Use in people without HIV lipodystrophy falls outside the label [2].

Prescription status and handling

The FDA database lists Egrifta as a prescription drug [1]. Handling depends on which product is dispensed. The Egrifta SV label describes reconstituting the 2 mg vial with 0.5 mL of the supplied Sterile Water for Injection, giving 0.35 mL (1.4 mg) immediately, and discarding any unused solution [2]. The Egrifta WR label describes reconstituting the 11.6 mg vial with 1.3 mL of Bacteriostatic Water for Injection, which contains benzyl alcohol, and giving 0.16 mL (1.28 mg) daily. One reconstituted vial supplies 7 daily doses, and unused solution is discarded 7 days after mixing [3]. The Egrifta SV label specifies injection into the abdomen with rotating sites, and says to avoid scar tissue, bruises and the navel [2]. The labels state that Egrifta SV and Egrifta WR are not substitutable, with different doses, vial numbers, reconstitution and storage requirements [3].

The labels also build in monitoring. They tell prescribers to evaluate glucose status before starting and to monitor periodically. They also say to monitor IGF-1 during therapy, and to consider discontinuing when IGF-1 stays elevated (for example above 3 SDS), particularly if fat loss is not robust [2].

What the trials show

The 2007 New England Journal of Medicine trial by Falutz and colleagues randomized 412 HIV-infected adults with abdominal fat accumulation to tesamorelin 2 mg daily or placebo for 26 weeks [6]. Visceral adipose tissue on CT fell 15.2% with tesamorelin and rose 5.0% with placebo. Triglycerides fell 50 mg/dL versus a rise of 9 mg/dL. The ratio of total to HDL cholesterol fell 0.31 versus a rise of 0.21. IGF-1 rose 81.0% versus a fall of 5.0% (P<0.001 for all) [6]. Glycemic measures did not differ significantly, and more tesamorelin patients withdrew because of adverse events [6]. The label reports the same trial as a visceral fat change of -27 versus +4 cm2, a difference of -31 cm2 (95% CI -39 to -24) [2].

A second trial of 404 patients, published in JAIDS in 2010, randomized patients 2:1 to 2 mg daily or placebo [8]. At 6 months visceral fat fell 10.9% (-21 cm2) versus 0.6% (-1 cm2) on placebo (P<0.0001), with improvement in trunk fat, waist circumference and waist-hip ratio, no change in limb or abdominal subcutaneous fat, and no change in glucose parameters [8]. A pooled analysis of the two phase 3 trials (806 patients: 543 tesamorelin, 263 placebo) found visceral fat change of -24 versus +2 cm2 at week 26, a treatment effect of -15.4%, with triglycerides -37 versus +6 mg/dL and IGF-1 +108 versus -7 ng/mL [9].

Two smaller trials looked at liver fat, which is not an approved use. In the 50-patient trial by Stanley and colleagues in JAMA (28 on tesamorelin, 22 on placebo), visceral fat changed by -34 versus +8 cm2 (treatment effect -42 cm2, 95% CI -71 to -14) and liver fat by a median -2.0% versus +0.9% [10]. In the 2019 Lancet HIV trial in people with HIV and fatty liver, 61 people were enrolled and 30 per arm were analyzed. Liver fat fell by an absolute 4.1 percentage points more than placebo (95% CI -7.6 to -0.7), a 37% relative reduction, and 35% versus 4% reached liver fat below 5%. Glucose and HbA1c did not differ [11]. FDA has not approved tesamorelin for fatty liver [11].

The phase 3 trials were conducted before integrase inhibitors were introduced. A secondary analysis of the 61-person liver-fat trial looked at 38 participants on integrase inhibitor regimens at baseline. Visceral fat changed by a median -25 cm2 with tesamorelin versus +14 cm2 with placebo (P=0.001), and hepatic fat by -4.2% versus -0.5% (P=0.01). Adverse events, including hyperglycemia, occurred with similar frequency in both groups [12].

Does the effect last?

Not on the label's extension data. Patients treated with tesamorelin for the first 26 weeks and then continued for another 26 weeks had a mean visceral fat change from week 26 to week 52 of 0% (Study 1) and -5% (Study 2). Those re-randomized to placebo had +22% and +16% [2].

What people on Reddit report

Reddit accounts from people who used tesamorelin for fat loss, describing whether results held after stopping, how long they ran it, and what it cost them.

BluejayEuphoric3606 · Peptidesource

You're referencing the studies for Tesa, correct? The reason the visceral fat returned was due to the patient population. These patients had HIV, and the medications that they take cause lipodystrophy. That said, if you were to continue to eat a bad diet, not exercise, etc then of course it could return.

Argues the fat returned in the studies because of the HIV population and their lipodystrophy, and that diet and exercise still determine what happens after stopping.

Read the source discussion

anukamrussj · Peptidesource

Clinical trials had patients on Tesa for over a year. It can be used long-term. If you can afford it, do at least 16 weeks. You'll be fine.

Says trial patients took it for over a year and that long-term use is fine, advising a full course if the person can afford it.

Read the source discussion

Key_War_7470 · Peptidesource

Was on TESA for about 8 weeks, had good results at recommend dosing but I stopped after 8 because I didn't want to take any chances. This is entirely up to the user and should not be based on other people's protocols. Cycling off and on would be prudent.

Ran a short course, stopped on purpose, and advises cycling on and off rather than copying other people's protocols.

Read the source discussion

Abstract-Impressions · Peptidesource

I used Tirzepitide to do all the heavy lifting and get rid of my visceral fat, and started Tesa to get rid of my love handles after I hit my goal weight but still had some fat pockets. Tesa's kinda spendy to do long term.

Used a different drug for most of the fat loss, then added tesamorelin for leftover pockets and found it costly to continue long term.

Read the source discussion

What the label says to watch for

IGF-1 rises often. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS, seen as early as 13 weeks. Among those treated for 52 weeks, the figures were 34% and 23% [2]. The effects of prolonged IGF-1 elevation are unknown [2].

Glucose is the label's other main concern. An HbA1c of 6.5% or higher from baseline to week 26 occurred in 5% of tesamorelin patients versus 1% on placebo, a hazard odds ratio of about 3.3 (95% CI 1.4 to 9.6). The label asks prescribers to monitor people with diabetes for potential development or worsening of retinopathy [2].

Fluid retention is labeled, and may show up as edema, joint pain or carpal tunnel syndrome [2]. Hypersensitivity reactions occurred in 4% of patients in trials and included itching, redness, flushing, hives and rash. The label advises patients to seek prompt medical attention and says to discontinue the drug if a reaction is suspected [2]. Injection-site reactions occurred in 25% of tesamorelin patients versus 14% on placebo during the first 26 weeks [2]. The most commonly reported reactions, above 5%, were arthralgia, injection-site erythema, injection-site pruritus, pain in an extremity, peripheral edema and myalgia. In the label's combined table, arthralgia was 13% versus 11%, peripheral edema 6% versus 2%, and myalgia 6% versus 2% [2].

Tesamorelin induces release of growth hormone, a known growth factor. The label asks prescribers to weigh the higher background cancer risk in people with HIV and to discontinue if malignancy recurs [2]. It also notes that pharmacologic growth hormone has been linked to increased mortality in acute critical illness, and says to consider discontinuing in critically ill patients [2].

With the original 1 mg/vial product, anti-tesamorelin IgG antibodies were found in 50% of patients at 26 weeks and 47% at 52 weeks, and in 85% of those with hypersensitivity reactions. Visceral fat reduction and IGF-1 response were similar with and without antibodies [2]. Two interaction notes concern other prescriptions. The label says patients receiving glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting, with cortisone acetate and prednisone affected more than other steroids. It also reports that tesamorelin changed simvastatin exposure by about -8% and ritonavir exposure by about -9% (AUC) in healthy subjects, which the label calls no significant impact [2].

Questions worth asking

Choose the questions you want to keep

Compounded tesamorelin sold online

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [5]. FDA has not placed tesamorelin on its list of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026). Tesamorelin also appears in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [13][14][15]. It is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [4][5]. FDA has made no category-based statement about compounding this peptide [13][14][15].

Competition and testing

WADA's Prohibited List names tesamorelin in S2.2.4, the growth hormone releasing factors class, and prohibits it at all times, in and out of competition [7]. It is on the 2026 List and stays on the 2027 List [7][16].

Brand product versus compounded vial

The approved product is a brand drug licensed under BLA 022505 and sold as Egrifta SV or Egrifta WR [1][2][3]. A compounded vial sold online falls outside that approval [4][5].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. How does the FDA database classify Egrifta?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Do I need a prescription for tesamorelin?
Yes. Egrifta is listed as a prescription drug, and the labels cover two manufactured products: Egrifta SV at 1.4 mg daily and Egrifta WR at 1.28 mg daily, which are not substitutable [1][2][3].
Who is a candidate for Egrifta?
The approved population is HIV-infected adults with lipodystrophy and excess abdominal fat. The pivotal trials enrolled adults aged 18 to 65 with waist circumference of at least 95 cm in men or 94 cm in women and fasting glucose below 150 mg/dL [2]. Active malignancy, disruption of the hypothalamic-pituitary axis, hypersensitivity and pregnancy are contraindications [2][3].
What results do the trials show?
In the 412-patient NEJM trial, visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo over 26 weeks, with triglycerides down 50 mg/dL versus up 9 mg/dL [6]. A 404-patient trial found a 10.9% visceral fat reduction versus 0.6% on placebo [8].
Does visceral fat return after stopping?
In the label's extension data, patients switched to placebo after 26 weeks had visceral fat rise 16% to 22%, while those who continued had changes of 0% to -5% [2].
Is tesamorelin on FDA's compounding risk list?
No. Tesamorelin is not on FDA's page of bulk substances that may present significant safety risks when compounded, and it appears in no category of FDA's lists for state-licensed pharmacies and physicians or for outsourcing facilities [13][14][15]. It is also not one of the six peptides in HHS's draft enforcement-discretion policy [4][5].
Is Egrifta approved for weight loss?
No. The label says it is not indicated for weight loss management because it has a weight-neutral effect. Its only approved use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy [2].
Show all 17 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Official web page.
  5. Official web page.
  6. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
  7. World Anti-Doping Agency.
  8. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
  9. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
  10. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9.
  11. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
  12. Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764.
  13. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  14. U.S. Food and Drug Administration.
  15. U.S. Food and Drug Administration.
  16. World Anti-Doping Agency.
  17. Reddit participants. Has anyone here used Tesamorelin long-term and managed to keep the fat off after stopping? (r/Peptidesource). Accessed 2026-11-11.
Evidence overview for Egrifta (Tesamorelin) Online: Cost, Candidacy, and What the Evidence Shows